GM-CSF spray for autoimmune pulmonary alveolar proteinosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new way to deliver a protein called GM-CSF directly into the lungs through a tube during a bronchoscopy. It may help people with autoimmune pulmonary alveolar proteinosis (aPAP) breathe better and improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with autoimmune pulmonary alveolar proteinosis (aPAP).
- You have symptoms like shortness of breath, coughing, or trouble breathing after activity, or your oxygen levels or lung function are below normal.
- You have not had other treatments for PAP (like whole lung lavage or inhaled GM-CSF) in the last 4 weeks.
- You are willing to sign a consent form to participate.
- You do not have other lung diseases, severe heart or blood conditions, cancer, or are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
This program provides an experimental inhaled medication to people with a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP), where the immune system attacks the lungs. The treatment, molgramostim, is given through a nebulizer and may help improve breathing and reduce symptoms.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Hear when a new Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.